Drug Trial Radar · NCT04358393
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
69
Planned (sponsor's estimate)
Start
Dec 4, 2020
Primary completion
Dec 30, 2024
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two Part study in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or high risk myelodysplastic syndrome (MDS) that will initially evaluate the safety and tolerability of APG-115 as a single agent in Part 1, followed by a combination of APG-115 + 5-azacitidine (5-AZA) in Part 2.
Conditions
- AML
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- CMML
- Myelodysplastic Syndromes
- High-risk Myelodysplastic Syndrome
- MDS
Interventions
APG-115Drug
APG-115 given once daily on day 1-5 of every 28 day cycle
5-azacitidineDrug
5-AZA is given at 75 mg/m˄2/d subcutaneously daily on Day 1-7 every 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated DoseTime frame: 28 days
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Duke University
Durham, North Carolina · Recruiting
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas · Recruiting
MD Anderson
Houston, Texas · Recruiting
Texas Oncology - Tyler
Tyler, Texas · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
Seattle Cancer Care Alliance
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.